MACSF

COMMUNIQUÉS West-GlobeNewswire

Oxford Biomedica completes acquisition of ABL Europe
29/01/2024
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK [...]
Applied UV Inc. Announces Receipt of Provisional Patent for Our Pulse Modulated UVC LED System to be Added to Our Patented Fighter Flex LED Solution Expanding Significant Revenue Opportunity
29/01/2024
DENVER, CO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Applied UV Inc. (NASDAQ: AUVI), a leader in smart building technology solutions, announced the introduction of its industry disruptive pulse modulated [...]
Fortrea Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call
29/01/2024
DURHAM, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2023 [...]
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
29/01/2024
BAUDETTE, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the [...]
21e Guignolée Dr Julien : Montant historique de 4,2 M$ pour les enfants en situation de vulnérabilité
29/01/2024
Un appel à la générosité entendu à travers tout le Québec Des bénévoles quêtent dans les rues de Montréal à l’occasion de la 21 e Guignolée Dr Julien. MONTRÉAL, 29 janv. 2024 (GLOBE NEWSWIRE) -- La Fondation Dr Julien [...]
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
29/01/2024
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to [...]
Oculis to Present at Upcoming February Investor Conferences
29/01/2024
ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that [...]
KFSH&RC-Madinah Receives Prestigious 2023 Press Ganey Human Experience Guardian of Excellence Award
29/01/2024
RIYADH, Saudi Arabia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Madinah has won the 2023 Human Experience Guardian of Excellence Award by Press Ganey for [...]
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29/01/2024
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious [...]
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
29/01/2024
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]
Gamida Cell Actively Pursuing Strategic Alternatives
29/01/2024
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic alternatives in [...]
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner
29/01/2024
Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, [...]
Completion of the combination between Novozymes and Chr. Hansen
29/01/2024
January 29, 2024 – Company announcement no. 2 Please see attachment. CONTACT INFORMATION Investor Relations Tobias Cornelius Bjorklund +45 3077 8682 tobb@novozymes.com Anders Enevoldsen +45 5350 1453 adev@novozymes.com [...]
Completion of the combination between Novozymes and Chr. Hansen
29/01/2024
Please read the full announcement in PDF Attachment 2024_02_Completion_Of_The_Combination
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29/01/2024
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated for the treatment [...]
Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
29/01/2024
ORION CORPORATION PRESS RELEASE 29 JANUARY 2024 at 11.00 EET Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain Orion Corporation (“Orion”) and [...]
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29/01/2024
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia ® in healthy adult subjects, met its primary endpoints Prolia ® and Xgeva ® (denosumab) are indicated for the [...]
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
29/01/2024
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of [...]
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
29/01/2024
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une nouvelle méthode [...]

Pages